Ajanta Pharma Ltd vs Astrazeneca Pharma India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Ajanta Pharma Ltd is ₹ 2900 as of 05 May 15:30 . The P/E Ratio of Ajanta Pharma Ltd changed from 23.9 on March 2021 to 35.7 on March 2025 . This represents a CAGR of 8.36% over 5 yearsThe P/E Ratio of Astrazeneca Pharma India Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Ajanta Pharma Ltd changed from ₹ 15517 crore on March 2021 to ₹ 32708 crore on March 2025 . This represents a CAGR of 16.08% over 5 yearsThe Market Cap of Astrazeneca Pharma India Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Ajanta Pharma Ltd for the Mar '26 is ₹ 1483 crore as compare to the Dec '25 revenue of ₹ 1399 crore. This represent the growth of 5.95% The revenue of Astrazeneca Pharma India Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Ajanta Pharma Ltd for the Mar '26 is ₹ 394.84 crore as compare to the Dec '25 ebitda of ₹ 407.21 crore. This represent the decline of -3.04% The ebitda of Astrazeneca Pharma India Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Ajanta Pharma Ltd changed from ₹ 245.77 crore to ₹ 266.7 crore over 8 quarters. This represents a CAGR of 4.17% The net profit of Astrazeneca Pharma India Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The Dividend Payout of Ajanta Pharma Ltd changed from 12.23 % on March 2021 to 38.28 % on March 2025 . This represents a CAGR of 25.63% over 5 yearsThe Dividend Payout of Astrazeneca Pharma India Ltd changed from 5.36 % on March 2021 to 69.12 % on March 2025 . This represents a CAGR of 66.76% over 5 years .

About Ajanta Pharma Ltd

Ajanta Pharma Limited is a specialty pharmaceutical formulation company primarily with a well-diversified Branded Generics business spread across India, the Rest of Asia, and Africa.
The Company is involved in development, manufacturing and marketing of quality finished dosages in domestic and international markets.
It produces a comprehensive range of specialty products targeting different therapeutic segments.
It has strong chronic-focused product portfolio led by a first-to-market strategy and front-end presence which helps it outgrow the market. The company's business includes Branded Generics in emerging markets of Asia and Africa, Generics in the developed markets of USA and Institution sales.
The branded generics business is spread in India and more than 30 emerging countries across Africa, CIS, the Middle East and South East Asia.

About Astrazeneca Pharma India Ltd

AstraZeneca Pharma India Limited (APIL) was incorporated on July 11, 1979.
The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company.
The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology. AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital.
Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company.

FAQs for the comparison of Ajanta Pharma Ltd and Astrazeneca Pharma India Ltd

Which company has a larger market capitalization, Ajanta Pharma Ltd or Astrazeneca Pharma India Ltd?

Market cap of Ajanta Pharma Ltd is 36,283 Cr while Market cap of Astrazeneca Pharma India Ltd is 20,116 Cr

What are the key factors driving the stock performance of Ajanta Pharma Ltd and Astrazeneca Pharma India Ltd?

The stock performance of Ajanta Pharma Ltd and Astrazeneca Pharma India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Ajanta Pharma Ltd and Astrazeneca Pharma India Ltd?

As of May 5, 2026, the Ajanta Pharma Ltd stock price is INR ₹2904.15. On the other hand, Astrazeneca Pharma India Ltd stock price is INR ₹8046.55.

How do dividend payouts of Ajanta Pharma Ltd and Astrazeneca Pharma India Ltd compare?

To compare the dividend payouts of Ajanta Pharma Ltd and Astrazeneca Pharma India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.